Requires certain health insurance issuers to certify that at least a majority of prescription drug rebates are provided to patients at the point of sale.
Summary
Bill S02128 mandates that health insurance issuers in New York must ensure that at least 85% of prescription drug rebates are passed on to patients at the point of sale. This is intended to reduce the out-of-pocket costs for enrollees when purchasing prescription medications. The bill also requires insurers to submit annual certifications to the superintendent of insurance, confirming compliance with this rebate distribution requirement. Additionally, the bill includes provisions for maintaining the confidentiality of rebate amounts received by insurers, protecting sensitive financial information from public disclosure.
Impact
If enacted, this bill will significantly alter the way prescription drug costs are handled by health insurers in New York. It aims to lower the financial burden on patients by ensuring that a substantial portion of rebates from drug manufacturers is directly applied to reduce their costs at the pharmacy counter. This change could lead to enhanced affordability of medications for consumers and may influence how insurers negotiate rebates with pharmaceutical companies. The bill also reinforces the confidentiality of rebate information, which may affect transparency in the pharmaceutical pricing landscape.
Sentiment
The sentiment surrounding Bill S02128 appears to be overwhelmingly positive, as evidenced by the unanimous support in committee votes and a strong majority in the final Senate floor vote. The discussions indicate a shared recognition of the need for greater fairness in prescription drug pricing and a commitment to improving patient access to affordable medications.
Contention
While there is broad support for the bill, some contention may arise regarding the confidentiality provisions, which could be seen as limiting transparency in the rebate process. Critics may argue that without public disclosure of rebate amounts, it becomes challenging to assess the true impact of these rebates on drug pricing and patient costs. However, proponents argue that protecting sensitive financial information is crucial for maintaining competitive practices among insurers.
Same As
Requires certain health insurance issuers to certify that at least a majority of prescription drug rebates are provided to patients at the point of sale.
Requires certain health insurance issuers to certify that at least a majority of prescription drug rebates are provided to patients at the point of sale.
Requires certain health insurance issuers to certify that at least a majority of prescription drug rebates are provided to patients at the point of sale.